CMS, FDA announce new program to speed up Medicare coverage of breakthrough medical devices
fiercehealthcare - The Trump administration unveiled a new program to speed up Medicare coverage for breakthrough devices, touting that the new pathway cuts red tape for medical device companies to gain reimbursement. CMS said it will pause the existing TCET pathway.
AI Summary: CMS and the Food and Drug Administration launched a coordinated program to accelerate Medicare coverage for breakthrough medical devices, aiming to shorten the gap between regulatory approval and patient access. The initiative aligns agency review processes, defines eligibility, and seeks faster coverage decisions while maintaining safety and evidentiary standards.
- New imaging and monitoring devices promise faster, remote patient care. (3)
- On scene: agencies align to speed device approvals and coverage. (6)
New imaging and monitoring devices promise faster, remote patient care.
On scene: agencies align to speed device approvals and coverage.
FDA approves 1st 2-drug HIV treatment
Ella Jeffries / beckershospitalreview - The FDA has approved Merck’s once-daily, two-drug regimen for adults with virologically suppressed HIV-1. The treatment combines 100 mg doravirine and 0.25 mg islatravir and is indicated for patients with no history of virologic treatment failure and no k…
AI Summary: The FDA has approved Merck’s once‑daily two‑drug antiretroviral regimen, marking a notable market entrant poised to compete with established single‑pill therapies. Regulators cleared the novel combination on efficacy and safety data, setting up potential shifts in prescribing, pricing and competition — and giving Gilead something new to grumble about.
Should you really trust health advice from an AI chatbot?
bbc - Abi has had very mixed results when asking a chatbot for guidance about her health issues.
AI Summary: Recent analyses and a hospital study reveal mainstream AI chatbots frequently provide incorrect or misleading medical guidance and miss initial diagnoses, posing real patient‑safety risks. The research shows these systems can fabricate facts, overconfidently assert dubious recommendations and fail to flag uncertainty, prompting calls for clinician oversight, clearer warnings and tighter evaluation before trusting bots with health decisions.
- Chatbots misdiagnose and confidently give dangerous medical advice (4)
- Companies race to build clinical AI tools and invest heavily (4)
- Other AI healthcare stories: innovation, payers, workflows, mental health trials (12)
- Researchers demand proof and robust evaluation before clinical AI deployment (5)
- Utah pilots bold AI medical programs, sparking safety debates (3)
- All Other Stories
Chatbots misdiagnose and confidently give dangerous medical advice
Companies race to build clinical AI tools and invest heavily
Other AI healthcare stories: innovation, payers, workflows, mental health trials
Researchers demand proof and robust evaluation before clinical AI deployment
Utah pilots bold AI medical programs, sparking safety debates
All Other Stories
FDA updates mifepristone safety study status
Ella Jeffries / beckershospitalreview - The FDA updated its mifepristone guidance, detailing ongoing work on a safety study and the current status of the drug’s Risk Evaluation and Mitigation Strategy program. According to an April 8 news release, the agency said it is still collecting and eval…
AI Summary: The FDA updated the safety review status for mifepristone, yet the regulatory change hasn’t translated into widespread retail availability. Many community pharmacies are still hesitant to dispense the drug due to logistical, legal and reputational concerns, leaving access limited despite federal moves intended to broaden distribution — so yes, policy changed, but practice lagged.
FDA approves Travere's Filspari as first drug for the kidney disease called FSGS
Nicole DeFeudis / endpoints - The FDA expanded the label for Filspari on Monday to add another kidney condition. The drug is now the first therapy approved in the US for focal segmental glomerulosclerosis (FSGS). The pill may be taken ...
AI Summary: The FDA approved Filspari for focal segmental glomerulosclerosis (FSGS), delivering the first specifically authorized treatment for this rare kidney disease. The approval provides a targeted therapeutic option for patients and marks a commercial milestone for Travere, raising hopes for better outcomes while spotlighting questions about access, pricing, and long‑term real‑world effectiveness.
One lot of Xanax recalled nationwide over quality issue, FDA says
medicalxpress - A widely used anxiety medication is being pulled from shelves due to "failed dissolution specifications," the U.S. Food and Drug Administration (FDA) said.
AI Summary: Regulators have flagged a quality issue and a manufacturer has recalled a specific lot of Xanax nationwide. Pharmacies and patients have been advised to check lot numbers and return affected pills; health officials emphasize the recall is precautionary, urging anyone with concerns to consult their pharmacist or clinician rather than panic-buy substitutes.
FDA to review whether to allow more access to certain peptides
medicalxpress - The U.S. Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies.
AI Summary: The FDA is moving toward expanding access to certain compounded peptides, opening a regulatory review that could loosen limits on how pharmacies and clinics obtain and prepare these popular therapies. The review balances potential patient demand and shortages against safety and quality-control concerns, putting compounding practices squarely under the spotlight.
Anti-amyloid Alzheimer's drugs show no clinically meaningful effect
medicalxpress - Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new review in the Cochrane Database of Systematic Reviews has found.
AI Summary: A major review concludes anti-amyloid Alzheimer’s medications show no clinically meaningful effect on patients’ cognition or daily function, prompting renewed debate about drug approvals, prescribing and research priorities. The analysis calls for careful reassessment of treatment value, clearer communication to patients and tighter scrutiny of future trials.
- Anti-amyloid drugs fall short: little benefit, safety risks (5)
- New biomarkers and imaging reshape Alzheimer’s diagnosis timing (3)
- Social and care issues: loneliness, memory and treatment decisions (2)
- All Other Stories
Anti-amyloid drugs fall short: little benefit, safety risks
New biomarkers and imaging reshape Alzheimer’s diagnosis timing
Social and care issues: loneliness, memory and treatment decisions
All Other Stories
New drug doubles 1-year survival in pancreatic cancer trial
medicalxpress - Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer.
AI Summary: A Phase 3 study showed a novel agent markedly lengthened survival for people with metastatic pancreatic cancer, roughly doubling one-year survival versus standard care. The results, from the RASolute 302 program evaluating daraxonrasib/Revolution Medicines’ approach, represent an uncommon advance in a stubbornly lethal disease and could change treatment standards pending regulatory review.
- Clinicians celebrate landmark KRAS win; cautious optimism prevails (7)
- Daraxonrasib Phase 3: drug doubles one-year survival (5)
- Market scramble: Revolution Medicines' fundraising and buyout buzz (3)
- Other pancreatic research, methods and early-stage KRAS studies (5)
- All Other Stories
Clinicians celebrate landmark KRAS win; cautious optimism prevails
Daraxonrasib Phase 3: drug doubles one-year survival
Market scramble: Revolution Medicines' fundraising and buyout buzz
Other pancreatic research, methods and early-stage KRAS studies
All Other Stories
FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
esmo - Evidence for efficacy is based on the findings from the ROSELLA study
AI Summary: The FDA granted marketing authorization for relacorilant in combination with nab‑paclitaxel to treat platinum‑resistant epithelial ovarian, fallopian tube and primary peritoneal cancers. Regulators cited clinical benefit in a difficult‑to‑treat population, providing an additional therapeutic option for patients with limited choices and marking an important regulatory milestone.
RFK Jr. launching health podcast to expose ‘hypocrisy’ and ‘corruption’
fiercehealthcare - Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services (HHS) secretary framed the podcast as a response to public health problems that he said have made “many of us ... come to the conc…
AI Summary: Robert F. Kennedy Jr. is debuting a health-focused podcast promising to call out what he characterizes as hypocrisy and corruption in medicine and public health. The show aims to amplify skeptical takes on mainstream health institutions and policies, positioning itself as a combative platform for contrarian voices and investigations.
FDA identifies eight deaths tied to Amgen's Tavneos
Max Bayer / endpoints - The FDA on Tuesday flagged more than 70 cases of severe liver injury and eight deaths associated with Amgen’s autoimmune treatment Tavneos, but the company said it previously notified the agency about the risk of ...
AI Summary: The FDA has tied eight patient deaths to Amgen’s drug Tavneos, prompting heightened regulatory review and industry concern. Reports outline safety signals and agency actions as clinicians and manufacturers reassess risk‑benefit profiles, while regulators weigh labeling, monitoring or other interventions to protect patients.
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong
abcnews - Federal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs
AI Summary: The FDA issued warnings over promotional materials and public statements related to a cancer drug associated with a biotech entrepreneur, finding claims that could mislead patients and investors. The agency asked the company to correct materials and refrain from unsubstantiated efficacy or safety assertions while oversight and compliance reviews continue.
FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs
Frank Vinluan / medcitynews - Denali Therapeutics’ Avlayah received FDA approval for treating Hunter syndrome, a rare neurological disorder. The biologic medicine uses Denali’s proprietary drug delivery technology to cross the protective blood-brain barrier. The post FDA Approval for …
AI Summary: Regulators granted Denali accelerated approval for a brain‑penetrant therapy, recognizing promising early efficacy in a rare neurological indication and addressing unmet needs in CNS drug delivery. The pathway requires confirmatory trials to verify clinical benefit while enabling earlier patient access to a novel mechanism targeting central nervous system disease.
FDA approves 1st weekly basal insulin for Type 2 diabetes
Ella Jeffries / beckershospitalreview - The FDA has approved Novo Nordisk’s Awiqli (insulin icodec-abae), making it the first once-weekly basal insulin available in the U.S. for adults with Type 2 diabetes. Awiqli is indicated as an adjunct to diet and exercise and is intended to reduce injecti…
AI Summary: The FDA approved the first once‑weekly basal insulin for adults with Type 2 diabetes, providing an alternative to daily injections and aiming to improve adherence and glycemic control. Regulators based the decision on trials showing comparable efficacy and safety to daily basal insulins, potentially reshaping diabetes management.
FDA approves Rocket's gene therapy for ultra-rare immune disease
Lei Lei Wu / endpoints - A rare disease gene therapy from Rocket Pharmaceuticals has garnered FDA approval after an earlier rejection for manufacturing problems. The FDA on Thursday granted accelerated approval to Rocket Pharma’s gene therapy ...
AI Summary: The FDA granted approval to Rocket’s gene therapy for a pediatric immune disorder, marking the first regulatory ok for this specific treatment class in children and offering a one‑time corrective option for affected patients. The decision opens access while raising expectations for long‑term follow‑up and real‑world safety monitoring.
Pfizer Lyme vaccine candidate heads to FDA
Ella Jeffries / beckershospitalreview - Pfizer and Valneva’s investigational Lyme disease vaccine candidate, PF-07307405 (LB6V), demonstrated more than 70% efficacy in preventing Lyme disease among individuals age 5 and older, according to topline phase 3 trial results. The prespecified analysi…
AI Summary: Pfizer is advancing a Lyme disease vaccine toward FDA submission despite a messy late‑stage picture: efficacy signals above 70% were reported while a pivotal trial missed its primary endpoint and struggled with low case numbers. Regulators must weigh public health need against statistical nuance as the company pushes for licensure.
‘Lack of Substantial Evidence’ Leads to FDA Rejection of Aldeyra Dry Eye Disease Drug
Frank Vinluan / medcitynews - Aldeyra said the FDA did not ask for another clinical trial for reproxalap in dry eye disease, but the drug’s mixed record in clinical testing warrants exploration about the reasons for failure, which could identify the appropriate patients for the eye dr…
AI Summary: The FDA has rejected Aldeyra’s reproxalap application, citing a lack of substantial evidence—marking the company’s third setback. Regulators did not demand a fresh, large trial but flagged inconsistent results, prompting investor angst and a slide in the stock. The decision underscores the gap between hopeful early data and regulatory standards.
F.D.A. Investigates 7 E. Coli Illnesses as Raw Dairy Farm Denies Any Link
Christine Hauser and Alice Callahan / nytimes - The outbreak has sickened people in California, Texas and Florida. The agency said Cheddar cheese products from Raw Farm are “the likely source,” but the company denies it and has not recalled them.
AI Summary: Federal investigators are probing seven E. coli infections across multiple states tied to cheddar cheese produced from raw milk. The implicated Raw Farm cheddar is the suspected source; the producer denies responsibility as public health officials trace exposures and warn consumers while urging caution around unpasteurized dairy.
FDA Drug Approval Marks a First for a Disease — But It’s Not Autism
Frank Vinluan / medcitynews - Leucovorin is now approved for cerebral folate deficiency months after FDA Commissioner Marty Makary claimed the decades-old generic drug had promise for treating autism. The FDA’s review was based on published literature and real-world evidence.The post …
AI Summary: The FDA has granted traditional approval to leucovorin for cerebral folate deficiency, formalizing a decades‑old generic’s role in a rare metabolic disorder. The decision comes amid earlier agency notes that evidence for autism benefit was weak and debate over expanding use without fresh trial data — cue the policy hot takes.